NCT00729053View on ClinicalTrials.gov

Study of IMO-2055 in Metastatic or Locally Recurrent Clear Cell Renal Carcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

92

Participants

Timeline

Start Date

June 30, 2004

Primary Completion Date

April 30, 2008

Study Completion Date

November 30, 2008

Conditions
Renal Cell Carcinoma
Interventions
DRUG

IMO-2055

immunostimulatory oligonucleotide

Trial Locations (1)

20007

Georgetown University, Lombardi Cancer Center, Washington D.C.

Sponsors
All Listed Sponsors
lead

Idera Pharmaceuticals, Inc.

INDUSTRY